The slow dissociation rate of K-1602 contributes to the enhanced inhibitory activity of this novel alkyl–aryl-bearing fluoroketolide

References

• Katz L, Ashley GW. Translation and protein synthesis: macrolides. Chem Rev 2005;105:499–527
   PubMed Web of Science ®Google Scholar
• Mankin AS. Macrolide myths. Curr Opin Microbiol 2008;11:414–21
   PubMed Web of Science ®Google Scholar
• Kannan K, Vázquez-Laslop N, Mankin AS. Selective protein synthesis by ribosomes with a drug-obstructed exit tunnel. Cell 2012;151:508–20
   PubMed Web of Science ®Google Scholar
• Menninger JR, Otto DP. Erythromycin, carbomycin, and spiramycin inhibit protein synthesis by stimulating the dissociation of peptidyl-tRNA from ribosomes. Antimicrob Agents Chemother 1982;21:811–18
   PubMed Web of Science ®Google Scholar
• Menninger JR. Mechanism of inhibition of protein synthesis by macrolide and lincosamide antibiotics. J Basic Clin Physiol Pharmacol 1995;6:229–50
   PubMedGoogle Scholar
• Tenson T, Lovmar M, Ehrenberg M. The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol 2003;330:1005–14
   PubMed Web of Science ®Google Scholar
• Wilson DN. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat Rev Microbiol 2014;12:35–48
   PubMed Web of Science ®Google Scholar
• Sutcliffe JA. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci 2011;1241:122–52
   PubMed Web of Science ®Google Scholar
• Bryskier A. Ketolides-telithromycin, an example of a new class of antibacterial agents. Clin Microbiol Infect 2000;6:661–9
   PubMed Web of Science ®Google Scholar
• Kirst HA. New macrolide, lincosaminide and streptogramine B antibiotics. Expert Opin Ther Pat 2010;20:1343–57
   PubMed Web of Science ®Google Scholar
• Rafie S, MacDougall C, James CL. Cethromycin: a promising new ketolide antibiotic for respiratory infections. Pharmacotherapy 2010;30:290–303
   PubMed Web of Science ®Google Scholar
• Llano-Sotelo B, Dunkle J, Klepacki D, et al. Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Antimicrob Agents Chemother 2011;54:4961–70
   Web of Science ®Google Scholar
• Krokidis MG, Márquez V, Wilson DN, et al. Insights into the mode of action of novel fluoroketolides, potent inhibitors of bacterial protein synthesis. Antimicrob Agents Chemother 2013;58:472–80
   PubMed Web of Science ®Google Scholar
• Vazquez-Laslop N, Thum C, Mankin AS. Molecular mechanism of drug-dependent ribosome stalling. Mol Cell 2008;30:190–202
   PubMed Web of Science ®Google Scholar
• Johansson M, Chen J, Tsai A, et al. Sequence-dependent elongation dynamics on macrolide-bound ribosomes. Cell Rep 2014;7:1534–46
   PubMed Web of Science ®Google Scholar
• Ramu H, Mankin A, Vazquez-Laslop N. Programmed drug dependent ribosome stalling. Mol Microbiol 2009;71:811–24
   PubMed Web of Science ®Google Scholar
• Vazquez-Laslop N, Klepacki D, Mulhearn DC, et al. Role of antibiotic ligand in nascent peptide-dependent ribosome stalling. Proc Natl Acad Sci USA 2011;108:10496–501
   PubMed Web of Science ®Google Scholar
• Bailey M, Chettiath T, Mankin AS. Induction of erm(C) expression by noninducing antibiotics. Antimicrob Agents Chemother 2008;52:866–74
   PubMed Web of Science ®Google Scholar
• Dinos G, Kalpaxis D. Studies on the interaction between a ribosomal complex active in peptide bond formation and the macrolide antibiotics tylosin and erythromycin. Biochemistry 2000;39:11621–8
   PubMed Web of Science ®Google Scholar
• Karahalios P, Kalpaxis D, Fu H, et al. On the mechanism of action of 9-O-arylalkyloxime derivatives of 6-O-mycaminosyltylonolide, a new class of 16-membered macrolide antibiotics. Mol Pharmacol 2006;70:1271–80
   PubMed Web of Science ®Google Scholar
• Krokidis MG, Kostopoulou ON, Kalpaxis DL, Dinos GP. Dissecting the ribosomal inhibition mechanism of a new ketolide carrying an aryl–alkyl group at C-13 of its lactone-ring. Int J Antimicrob Agents 2010;35:235–9
   PubMed Web of Science ®Google Scholar
• Morrison JF, Walsh C. The behavior and significance of slow-binding inhibitors. Adv Enzymol Relat Areas Mol Biol 1988;61:201–301
   PubMedGoogle Scholar
• Schramm VL. Transition state analogues and drug development. ACS Chem Biol 2013;8:71–81
   PubMed Web of Science ®Google Scholar
• Blaha G, Stelzl U, Spahn CMT, et al. Nierhaus. Preparation of functional ribosomal complexes and the effect of buffer conditions on tRNA positions observed by cryoelectron microscopy. Methods Enzymol 2000;317:292–309
   PubMed Web of Science ®Google Scholar
• Dinos G, Wilson DN, Teraoka Y, et al. Dissecting the ribosomal inhibition mechanisms of edeine and pactamycin: the universally conserved residues G693 and C795 regulate P-site RNA binding. Mol Cell 2004;13:113–24
   PubMed Web of Science ®Google Scholar
• Stern S, Moazed D, Noller HF. Structural analysis of RNA using chemical and enzymatic probing monitored by primer extension. Methods Enzymol 1988;164:481–9
   PubMed Web of Science ®Google Scholar
• Merryman C, Noller HF. Footprinting and modification-interference analysis of binding sites on RNA. In: Smith CWJ, ed. RNA: protein interactions, a practical approach. Oxford, United Kingdom: Oxford University Press; 1998:237–53
   Google Scholar
• Synetos D, Coutsogeorgopoulos C. Studies on the catalytic rate constant of ribosomal peptidyltransferase. Biochim Biophys Acta 1987;923:275–85
   PubMed Web of Science ®Google Scholar
• Hansen JL, Ippolito JA, Ban N, et al. The structures of four macrolide antibiotics bound to the large ribosomal subunit. Mol Cell 2002;10:117–28
   PubMed Web of Science ®Google Scholar
• Hermann T. Drugs targeting the ribosome. Curr Opin Struct Biol 2005;15:355–66
   PubMed Web of Science ®Google Scholar
• Shlaes DM, Moellering RC. Telithromycin and the FDA: implications for the future. Lancet Infect Dis 2008;8:83–5
   PubMed Web of Science ®Google Scholar
• Dinos G, Connell S, Nierhaus K, Kalpaxis D. Erythromycin, roxithromycin and clarithromycin: use of slow-binding kinetics to compare their in vitro interaction with a ribosomal complex active in peptide bond formation. Mol Pharmacol 2003;63:617–23
   PubMed Web of Science ®Google Scholar
• Kostopoulou ON, Petropoulos AD, Dinos GP, et al. Investigating the entire course of telithromycin binding to Escherichia coli ribosomes. Nucleic Acids Res 2012;40:5078–87
   PubMed Web of Science ®Google Scholar
• Erion MD, Walsh CT. 1-Aminocyclopropanephosphonate: time-dependent inactivation of 1-aminocyclopropanecarboxylate deaminase and Bacillus stearothermophilus alanine racemase by slow dissociation behavior. Biochemistry 1987;26:3417–25
   PubMed Web of Science ®Google Scholar
• Wu Z, Walch CT. Phosphinate analogs of D-,D-dipeptides: slow-binding inhibition and proteolysis protection of VanX, a d-,d-dipeptidase required for vancomycin resistance in Enterococcus faecium. Proc Natl Acad Sci USA 1995;92:11603–7
   PubMed Web of Science ®Google Scholar
• Lovmar M, Tenson T, Ehrenberg M. Kinetics of macrolide action: the josamycin and erythromycin cases. J Biol Chem 2004;279:53506–15
   PubMed Web of Science ®Google Scholar
• Petropoulos A, Kouvela E, Dinos G, Kalpaxis D. Stepwise binding of tylosin and erythromycin to Escherichia coli ribosomes, characterized by kinetic and footprinting analysis. J Biol Chem 2008;283:4756–65
   PubMed Web of Science ®Google Scholar
• Wilson DN, Harms JM, Nierhaus KH, et al. Species-specific antibiotic-ribosome interactions: implications for drug development. Biol Chem 2005;386:1239–52
   PubMed Web of Science ®Google Scholar
• Wilson DN. On the specificity of antibiotics targeting the large ribosomal subunit. Ann N Y Acad Sci 2011;1241:1–16
   PubMed Web of Science ®Google Scholar
• Schloss JV. Significance of slow-binding enzyme inhibition and its relationship to reaction-intermediate analogues. Acc Chem Res 1988;21:348–53
   Web of Science ®Google Scholar